ORCHID -Bexel Pharmaceuticals Inc 
ORCHID, in conjunction with its Indian R&D arm, USA drug discovery subsidiary, Bexel Pharmaceuticals Inc, and USA affiliate, Diakron Pharmaceuticals Inc, has new Drug Discovery programs in therapeutic areas of metabolic disorders, cardio-vascular, oncology, inflammation and anti-infectives.
It brings forth a rich pipeline of NCEs for out-licensing and recently received a milestone for an ongoing anti-infective collaboration with MERCK.
Orchid Chemicals & Pharmaceuticals Ltd. (ORCHID), an Indian Pharmaceutical company, of global standing and innovation is fuelling growth through R&D of novel small molecules and new pharmaceutical products backed by scientific, technical and manufacturing competencies and global intellectual property management.
ORCHID operates in business domains of APIs, finished dosage forms (Generics), New Drug Discovery(NCE), & Custom Research & Manufacturing Services (crams), while pursuing biotechnology based green chemistry initiatives and is assessing entry into Bio-Pharmaceuticals (bio-betters).
Orchid continues to expand its patent technologies, new chemical entities/product and services through various business propositions.
